The Application of Emodin Treatment on Nasopharyngeal Carcinoma Therapy.

EBV NPC therapy emodin nasopharyngeal carcinoma natural compound

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
21 Feb 2024
Historique:
received: 30 12 2023
revised: 02 02 2024
accepted: 08 02 2024
medline: 28 3 2024
pubmed: 28 3 2024
entrez: 28 3 2024
Statut: epublish

Résumé

Nasopharyngeal carcinoma (NPC) is a malignancy prevailing in Taiwan, Hong Kong, Southern China, Southeast Asia, and North Africa. Although early-stage NPC responds well to the primary treatment of radio-chemotherapy, the mortality rate of advanced NPC remains high. Therefore, developing new therapies for nasopharyngeal carcinoma is an urgent task. Emodin is an anthraquinone derivative mainly found in

Identifiants

pubmed: 38540100
pii: biomedicines12030486
doi: 10.3390/biomedicines12030486
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : China Medical University Hospital, Taiwan
ID : EXO-113-016
Organisme : National Science and technology council, Taiwan
ID : MOST 110-2320-B-039-009

Auteurs

Chung-Chun Wu (CC)

Translational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung City 404447, Taiwan.
National Institute of Cancer Research, National Health Research Institutes, Zhunan 350401, Taiwan.

Mei-Shu Chen (MS)

National Institute of Cancer Research, National Health Research Institutes, Zhunan 350401, Taiwan.

Jen-Yang Chen (JY)

National Institute of Cancer Research, National Health Research Institutes, Zhunan 350401, Taiwan.

Classifications MeSH